ClinicalTrials.gg
Not yet recruitingNCT07431255Updated Feb 24, 2026

Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease

An observational study in Alzheimer Disease (AD), sponsored by IRCCS San Raffaele. Not yet recruiting at 1 site in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by IRCCS San Raffaele · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
35
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.

Started
2026
with 3 others
Observational
6 of 10
4 open now
Registered
5th of 10
by date

Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 5th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alzheimer Disease by IRCCS San Raffaele, or all of them as a file.
02

Study summary

This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET) to assess Alzheimer's disease. This study will use existing scan data from patients who already had both scans as part of their routine care.

The AI model will try to generate the FDG PET image using only the Amyloid PET scan and an MRI. If successful, this method could reduce radiation exposure, costs, and time for future patients by eliminating the need for a separate FDG injection and scan.

No new scans, injections, or procedures will be performed for this study. All data will be fully anonymized (personal information removed) before analysis. The study involves approximately 35 adult patients (age 50+) whose data were collected between January 2025 and December 2025 at IRCCS Ospedale San Raffaele in Milan, Italy.

Read the detailed description

This is a retrospective observational study conducted at IRCCS Ospedale San Raffaele, Milan, Italy. The study evaluates the accuracy of synthetic [18F]FDG PET images generated using a SwinUNETR deep learning model compared to native [18F]FDG PET images.

Study Population:

Adults (≥ 50 years) who underwent amyloid PET imaging (using Florbetaben or Flutemetamol), structural MRI, and [18F]FDG PET due to cognitive symptoms between January 2025 and December 2025. Approximately 35 patients meeting inclusion criteria will be included.

Methodology:

All imaging and clinical data were collected as part of routine diagnostic care; thus, no additional procedures, interventions, or interactions with patients are required for this study. All data are fully deidentified before analysis, consistent with GDPR and institutional data protection policy. The SwinUNETR model processes volumetric images to generate synthetic FDG PET images from early-phase amyloid PET and MRI inputs.

Objectives and Endpoints:

Primary Objective: To quantitatively and qualitatively assess the accuracy of synthetic FDG PET images compared with native FDG PET images.

Primary Endpoint: Pearson correlation coefficient and mean absolute error (MAE) of SUVR values obtained from native FDG PET and synthetic FDG PET in Alzheimer relevant areas of interest (precuneus, posterior cingulate, lateral temporal cortex, and frontal cortex).

Secondary Objective: To assess visual interpretability and clinical intuitiveness of synthetic FDG PET images by expert nuclear medicine physicians.

Secondary Endpoint: Inter-rater agreement (Cohen's kappa) among 2 blinded nuclear medicine physicians rating synthetic FDG scans as "clinically acceptable" or not.

Ethical Considerations:

Due to the retrospective and non-interventional nature of this study, no additional informed consent is required. A waiver of informed consent will be requested from the Ethics Committee. The image data will be fully anonymized in accordance with institutional policies.

03

Conditions studied

  • Alzheimer Disease (AD)

Browse trials for

Keywords

  • Alzheimer Disease
  • Amyloid PET
  • FDG PET
  • Artificial Intelligence
  • Deep Learning
  • Retrospective Study
  • Neuroimaging
  • Positron Emission Tomography
  • Florbetaben
  • Flutemetamol
  • Image Processing
  • Diagnostic Imaging
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥50 years) with cognitive symptoms who underwent amyloid PET imaging (Florbetaben or Flutemetamol), structural MRI, and [18F]FDG PET at the Nuclear Medicine Department of IRCCS Ospedale San Raffaele, Milan, Italy, as part of routine diagnostic care between January 1, 2025 and December 31, 2025.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years at the time of imaging.
  • Clinically indicated amyloid PET scan performed with Florbetaben or Flutemetamol between January 1, 2025 and December 31, 2025.
  • Availability of paired structural MRI (3D T1-weighted) and real [18F]FDG PET scan acquired within ±6 months of the amyloid PET.
  • All three imaging modalities (Amyloid PET, FDG PET, MRI) are of sufficient technical quality for co-registration and quantitative analysis.

Exclusion criteria

Exclusion Criteria:

  • Presence of other major neurological disorders that may confound FDG metabolism (e.g., Parkinson's disease, frontotemporal dementia, brain tumor, or recent stroke).
  • Severe motion artifacts or technical failures in any of the three imaging modalities that prevent reliable co-registration or SUVR calculation.
  • Incomplete or irreversibly corrupted DICOM data preventing anonymization or conversion to analysis-ready format.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with cognitive impairment undergoing amyloid PET

    Adults (≥50 years) with cognitive symptoms who underwent amyloid PET (Florbetaben or Flutemetamol), structural MRI, and \[18F\]FDG PET at IRCCS Ospedale San Raffaele between January 2025 and December 2025 as part of routine diagnostic care. All data are fully anonymized prior to analysis.

06

What researchers measure

Primary outcomes

  1. Quantitative Accuracy of Synthetic FDG PET Images (SUVR Correlation and MAE)

    Pearson correlation coefficient and mean absolute error (MAE) of SUVR values obtained from native FDG PET and synthetic FDG PET in Alzheimer relevant areas of interest (precuneus, posterior cingulate, lateral temporal cortex, and frontal cortex).

    Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025

Secondary outcomes

  1. Regional SUVR Bias Between Synthetic and Native FDG Across Machine Types

    Regional SUVR bias (mean difference ± standard deviation) between synthetic and native FDG across machine types and reconstructions used at Ospedale San Raffaele.

    Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025

Other outcomes

  1. Effect of Amyloid Status on Synthetic FDG Generation Accuracy

    Stratified analysis of primary endpoint (SUVR correlation and MAE) by state of amyloid PET positivity (positive vs negative) based on established Centiloid or visual read criteria.

    Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet decided whether individual participant data will be shared. The research team will consider data sharing requests on a case-by-case basis, subject to institutional approval and data use agreements. Anonymized imaging data (NIfTI format) and analysis scripts may be made available upon reasonable request to the Principal Investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431255
Lead sponsor
IRCCS San Raffaele
Responsible party
Chiti Arturo (Arturo Chiti, IRCCS San Raffaele) — Principal investigator
First posted
Feb 24, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 24, 2026

Study contacts

Clinical Trial Center Nuclear Medicine Unit
Contact
mednuc@hsr.it
+39-02-2643-2716
CTC First Contact ctc.firstcontact@hsr.it
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion